Date: 2015-04-09
Type of information: Nomination
Compound:
Company: Osiris Therapeutics (USA - MD)
Therapeutic area: Regenerative Medicine
Type agreement: nomination
Action mechanism:
Disease:
Details: * On April 9, 2015, Osiris Therapeutics announced the promotion of Alla Danilkovitch, Ph.D., to serve as Chief Scientific Officer. Dr. Danilkovitch has been with Osiris since 2003; her expertise and leadership has guided the company in the development of groundbreaking scientific ideas in regenerative medicine. She has a proven record of successful product development from scientific ideas to market launch, which includes the world's first approved stem cell drug, remestemcel-L, for graft versus host disease as well as BIO4 ™ for bone repair, Cartiform® for cartilage repair and Grafix® for acute and chronic wounds. Recently, Dr. Danilkovitch and her team have developed a robust pipeline of early stage products based on cellular constructs in wound care and sports medicine.
Dr. Danilkovitch has over 25 years of broad biomedical research experience including stem cell biology, immunology and cancer research. Prior to joining Osiris in April 2003 , Dr. Danilkovitch conducted research at the National Cancer Institute of National Institutes of Health , the Max-Plank Institute of Biochemistry in Munich and at Moscow State University . Dr. Danilkovitch earned a Ph.D. degree in cell biology and an M.S. degree in cellular immunology and microbiology from Moscow State University .
Financial terms:
Latest news:
